A Rare Case Report of Neurological Condition: Moersch-Woltman Syndrome with Positive Anti-GAD Antibodies

Aakanksha Pitliya1

  • 1MBBS, Extern, Neurology Services Inc, Alexandria, Virginia, USA.

International Journal of Medical Students
|October 19, 2023
PubMed
Abstract

Insights

Moersch-Woltman Syndrome (MWS), or Stiff Person Syndrome (SPS), is a rare neurological disorder. Diagnosing MWS is challenging, but testing for glutamic acid decarboxylase (GAD) antibodies is crucial for confirmation.

Area of Science:

  • Neurology
  • Immunology

Background:

  • Moersch-Woltman Syndrome (MWS), also known as Stiff Person Syndrome (SPS), is a rare, progressive central nervous system disorder.
  • Characterized by immobility, rigidity, and painful muscle spasms, MWS affects women twice as frequently as men.
  • Prevalence is low, impacting 1-2 individuals per million, with symptoms exacerbated by external stimuli.

Purpose of the Study:

  • To highlight diagnostic challenges in Moersch-Woltman Syndrome (MWS).
  • To emphasize the significance of glutamic acid decarboxylase (GAD) antibodies in MWS diagnosis.
  • To present a case report illustrating MWS diagnosis and management.

Main Methods:

  • Case report of a 57-year-old female patient with symptoms of muscle spasms and stiffness.
  • Diagnostic workup included laboratory tests and imaging.
  • Confirmation of MWS through positive GAD antibody testing.

Main Results:

  • The patient presented with widespread muscle spasms and severe stiffness.
  • Diagnosis of MWS was confirmed by the presence of GAD antibodies.
  • Treatment with Clonazepam and Baclofen resulted in a 15-20% reduction in spasticity within three weeks.

Conclusions:

  • Anti-GAD antibodies are critical for confirming Stiff Person Syndrome (SPS) diagnosis.
  • Healthcare providers should consider GAD antibody testing for patients with suggestive symptoms.
  • A multidisciplinary approach is essential for comprehensive MWS patient care.